Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

Venetoclax, when added to the standard therapy of acute myeloid lymphoma and myelodysplastic syndrome show encouraging results. Venetoclax cause the self-destruction of the cancer cells.

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms.

Ganan-Gomez, I., et al. (2022) Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine. doi.org/10.1038/s41591-022 ...

Updated data from the BEXMAB study reveals a significant increase in complete remission rates for patients with high-risk ...

"Schrödinger ends development of blood cancer drug after patient deaths" was originally created and published by Clinical ...

NORTH CHICAGO, Ill., July 21, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax ...

Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) is caused by two distinct classes of stem ...

Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nature Communications, 2018; 9 (1) DOI: 10.1038/s41467-018-05984-x ...

Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined with Azacitidine (AZA) in Patients with Treatment-Naïve or Prior Venetoclax-Exposed Myeloid Malignancies Abstract #: 6505 Format: Oral Presentation ...